Related references
Note: Only part of the references are listed.BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain
Cyrille Sur et al.
BRAIN (2020)
Neurofilaments as biomarkers in neurological disorders
Michael Khalil et al.
NATURE REVIEWS NEUROLOGY (2018)
Current state of Alzheimer's fluid biomarkers
Jose Luis Molinuevo et al.
ACTA NEUROPATHOLOGICA (2018)
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease
Susanne Ostrowitzki et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
Jinping Wang et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Safety and tolerability of BAN2401-a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody
Veronika Logovinsky et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease
Gerald Novak et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-beta Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice
Stina Tucker et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Specific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain
Kristina Magnusson et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
Kaj Blennow et al.
ARCHIVES OF NEUROLOGY (2012)
Large Aggregates Are the Major Soluble Ab Species in AD Brain Fractionated with Density Gradient Ultracentrifugation
Dag Sehlin et al.
PLOS ONE (2012)
Heavy-Chain Complementarity-Determining Regions Determine Conformation Selectivity of Anti-A beta Antibodies
Dag Sehlin et al.
NEURODEGENERATIVE DISEASES (2011)
Polymorphic Structures of Alzheimer's β-Amyloid Globulomers
Xiang Yu et al.
PLOS ONE (2011)
Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer's disease
Delphine Boche et al.
ACTA NEUROPATHOLOGICA (2010)
Amyloid β-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils
Brian O'Nuallain et al.
JOURNAL OF NEUROSCIENCE (2010)
Revising the definition of Alzheimer's disease: a new lexicon
Bruno Dubois et al.
LANCET NEUROLOGY (2010)
Amyloid-beta Oligomers: Possible Roles as Key Neurotoxins in Alzheimer's Disease
Alex L. Lublin et al.
MOUNT SINAI JOURNAL OF MEDICINE (2010)
Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?
Gregory A. Jicha
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease
Anna Lord et al.
NEUROBIOLOGY OF DISEASE (2009)
Alzheimer's disease
Alistair Burns et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Molecular structural basis for polymorphism in Alzheimer's β-amyloid fibrils
Anant K. Paravastu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Aβ oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms
Marlen Knobloch et al.
JOURNAL OF NEUROSCIENCE (2007)
Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
NC Fox et al.
NEUROLOGY (2005)
Deciphering the molecular basis of memory failure in Alzheimer's disease
DM Walsh et al.
NEURON (2004)
Synaptic targeting by Alzheimer's-related amyloid β oligomers
PN Lacor et al.
JOURNAL OF NEUROSCIENCE (2004)
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
C Nilsberth et al.
NATURE NEUROSCIENCE (2001)
Share Paper
